Eli Lilly and Company (NYSE:LLY) Stock Position Decreased by Prentice Wealth Management LLC

Prentice Wealth Management LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 10.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,361 shares of the company’s stock after selling 155 shares during the period. Prentice Wealth Management LLC’s holdings in Eli Lilly and Company were worth $638,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Silicon Valley Capital Partners bought a new position in Eli Lilly and Company in the 1st quarter worth about $25,000. Bogart Wealth LLC grew its position in Eli Lilly and Company by 193.3% in the 1st quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock worth $30,000 after purchasing an additional 58 shares during the last quarter. Laffer Tengler Investments bought a new position in Eli Lilly and Company in the 1st quarter worth about $33,000. Tanglewood Legacy Advisors LLC bought a new position in Eli Lilly and Company in the 4th quarter worth about $37,000. Finally, Freedom Wealth Alliance LLC bought a new position in Eli Lilly and Company in the 4th quarter worth about $37,000. Institutional investors own 81.38% of the company’s stock.

Eli Lilly and Company Stock Down 1.2 %

LLY opened at $591.77 on Friday. The business has a 50 day moving average price of $507.52 and a 200 day moving average price of $434.64. Eli Lilly and Company has a twelve month low of $296.32 and a twelve month high of $601.84. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13. The firm has a market cap of $561.76 billion, a P/E ratio of 82.30, a price-to-earnings-growth ratio of 2.47 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The firm had revenue of $8.31 billion during the quarter, compared to analyst estimates of $7.58 billion. During the same period in the previous year, the company earned $1.25 EPS. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. Research analysts forecast that Eli Lilly and Company will post 9.84 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were issued a $1.13 dividend. The ex-dividend date was Monday, August 14th. This represents a $4.52 annualized dividend and a yield of 0.76%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 62.87%.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent analyst reports. Morgan Stanley upped their target price on shares of Eli Lilly and Company from $617.00 to $640.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 5th. 22nd Century Group restated a “maintains” rating on shares of Eli Lilly and Company in a research report on Tuesday, June 27th. Royal Bank of Canada upped their price target on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. UBS Group upped their price target on shares of Eli Lilly and Company from $447.00 to $498.00 and gave the stock a “buy” rating in a research note on Wednesday, May 24th. Finally, JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $510.00 to $600.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have given a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $532.78.

Insider Buying and Selling

In other news, EVP Alonzo Weems sold 1,148 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total transaction of $678,445.04. Following the completion of the transaction, the executive vice president now directly owns 7,760 shares in the company, valued at $4,586,004.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CAO Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $546.51, for a total transaction of $327,906.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,378 shares in the company, valued at $2,939,130.78. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Alonzo Weems sold 1,148 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total value of $678,445.04. Following the transaction, the executive vice president now owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,010,309 shares of company stock worth $21,095,701,670. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.